CATENA 150 MG
IDEBENONE : 150 MG · DIN 02314150 · SANTHERA PHARMACEUTICALS (SWITZERLAND) LIMITED
Health Canada status: CANCELLED POST MARKET
What is CATENA?
CATENA 150 MG contains IDEBENONE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02314150, held by SANTHERA PHARMACEUTICALS (SWITZERLAND) LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 30-Apr-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CATENA used for?
Symptomatic management of patients with Friedreich’s Ataxia. Authorized under NOC/c policy.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02314150 |
|---|---|
| Brand name | CATENA |
| Generic / active ingredient | IDEBENONE : 150 MG |
| Manufacturer | SANTHERA PHARMACEUTICALS (SWITZERLAND) LIMITED |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06BX13 IDEBENONE |
| AHFS class | 28:92.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Apr-2013 |
| Original market date | 2008-10-15 00:00:00 |
How is it administered?
Administer TID with food. Tablets must be swallowed whole. Dose based on weight (above/below 45 kg). Start at lower dose for 6 months before considering higher dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not specified in the provided text sections.
How is it supplied?
Not explicitly detailed in provided text (mentions "component of the container" and "bottles" is not specified).
Contraindications
Hypersensitivity to idebenone or ingredients; moderate or severe hepatic impairment; severe renal impairment.
Warnings and precautions
Rare reports of leucocytopenia and agranulocytosis; regular CBC monitoring required. Monitor liver function tests. Contains lactose and FD&C yellow No. 6 (potential allergen).
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.